1
|
Ishihara T, Nakamura Y, Sueyoshi K, Okamoto K, Tanaka H. Therapeutic interventions and the length of hospital stay for pediatric patients with COVID-19: a multicenter cohort study. Sci Rep 2023; 13:21450. [PMID: 38052970 PMCID: PMC10697937 DOI: 10.1038/s41598-023-48904-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 11/30/2023] [Indexed: 12/07/2023] Open
Abstract
The evidence for pediatric patients with COVID-19 was very limited, which was attributed to the small number of the cases as well as the rare incidence of severe pneumonia in this population. This retrospective cohort study aimed to identify the characteristics of pediatric patients with COVID-19 in the early period of the pandemic by analyzing Diagnosis Procedure Combination (DPC) data in Japan. This retrospective cohort analysis of Japanese multicenter research on COVID-19 using DPC data compared the outcomes and costs of treatment for pediatric patients with COVID-19. Of 4700 patients with COVID-19, 186 pediatric patients were included in this study. Among the included pediatric patients, 17 received therapeutic drugs specifically for COVID-19, while the remaining 169 pediatric patients received only symptomatic therapy. There were no significant differences in the length of hospital stay (9 vs. 8 days, p = 0.96), and medical cost (97,585 vs. 73,291 JPY) for the intervention and control groups, respectively by multiple regression analysis. This is the first epidemiological study to use DPC data to summarize the pathophysiology of pediatric patients in the early period of COVID-19 pandemic. There was no significant difference in length of hospital stay or medical cost by intervention.
Collapse
Affiliation(s)
- Tadashi Ishihara
- Department of Emergency and Critical Care Medicine, Juntendo University, Urayasu Hospital, 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021, Japan.
| | - Yuki Nakamura
- Department of Emergency and Critical Care Medicine, Juntendo University, Urayasu Hospital, 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021, Japan
| | - Koichiro Sueyoshi
- Department of Emergency and Critical Care Medicine, Juntendo University, Urayasu Hospital, 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021, Japan
| | - Ken Okamoto
- Department of Emergency and Critical Care Medicine, Juntendo University, Urayasu Hospital, 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021, Japan
| | - Hiroshi Tanaka
- Department of Emergency and Critical Care Medicine, Juntendo University, Urayasu Hospital, 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021, Japan
| |
Collapse
|
2
|
Otsuka Y, Hasegawa K, Yamamoto Y, Sato A, Omichi R, Otsuka F. Collaboration between generalist and ENT physicians in COVID-19 Omicron variant-induced laryngitis. Auris Nasus Larynx 2023; 50:652-653. [PMID: 36319505 PMCID: PMC9595371 DOI: 10.1016/j.anl.2022.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 09/23/2022] [Accepted: 10/19/2022] [Indexed: 06/16/2023]
Affiliation(s)
- Yuki Otsuka
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan; Emergency Center, Okayama City Hospital, 3-20-1 Kitanagase-omote-cho, Kita-ku, Okayama 700-8557, Japan.
| | - Kou Hasegawa
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
| | - Yukichika Yamamoto
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
| | - Asuka Sato
- Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
| | - Ryotaro Omichi
- Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
| | - Fumio Otsuka
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
| |
Collapse
|
3
|
Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, Imura H, Okano H, Narita C, Mayumi T, Yasuda H, Yamada K, Yamada H, Kawasaki T, Shime N, Doi K, Egi M, Ogura H, Aihara M, Kushimoto S, Nishida O. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). Acute Med Surg 2022; 9:e789. [PMID: 36267628 PMCID: PMC9579991 DOI: 10.1002/ams2.789] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2022] [Accepted: 09/07/2022] [Indexed: 12/15/2022] Open
Abstract
Background Coronavirus disease (COVID-19), an infectious disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J-SSCG) 2020 Special Committee created the Japanese Rapid/Living recommendations on drug management for COVID-19 using the experience of creating the J-SSCG. Methods The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of recommendations. The first edition of this guideline was released on September 9, 2020, and this is the revised edition (version 5.0; released on July 15, 2022). Clinical questions (CQs) were set for the following 10 drugs: favipiravir (CQ1), remdesivir (CQ2), corticosteroids (CQ4), tocilizumab (CQ5), anticoagulants (CQ7), baricitinib (CQ8), casirivimab/imdevimab (CQ9-1), sotrovimab (CQ9-2), molnupiravir (CQ10), and nirmatrelvir/ritonavir (CQ11). Recommendations Favipiravir is not suggested for all patients with COVID-19 (GRADE 2C). Remdesivir is suggested for patients with mild COVID-19 who do not require oxygen, and patients with moderate COVID-19 requiring supplemental oxygen/hospitalization (both GRADE 2B). Corticosteroids are recommended for moderate and severe COVID-19 (GRADE 1B, 1A). However, their administration is not recommended for mild COVID-19 (GRADE 1B). Tocilizumab is suggested for moderate and severe COVID-19 (GRADE 2B, 2C). Anticoagulant administration is recommended for moderate and severe COVID-19 (Good Practice Statement). Baricitinib is suggested for moderate and severe COVID-19 (both GRADE 2C). Casirivimab/imdevimab and sotrovimab are recommended for mild COVID-19 (both GRADE 2C). Molnupiravir and nirmatrelvir/ritonavir are recommended for mild COVID-19 (both GRADE 2C). SARS-CoV-2 mutant strains emerge occasionally, and each time, the treatment policy at clinics is forced to change drastically. We ask health-care professionals in the field to refer to the recommendations in these guidelines and use these to keep up to date with COVID-19 epidemiological information.
Collapse
Affiliation(s)
- Kazuma Yamakawa
- Department of Emergency and Critical Care MedicineOsaka Medical and Pharmaceutical UniversityTakatsukiJapan
| | - Ryo Yamamoto
- Department of Emergency and Critical Care MedicineKeio University School of MedicineTokyoJapan
| | - Takero Terayama
- Department of Psychiatry, School of MedicineNational Defense Medical CollegeTokorozawaJapan
| | - Hideki Hashimoto
- Department of Infectious DiseasesThe University of Tokyo HospitalTokyoJapan
| | - Tadashi Ishihara
- Department of Emergency and Critical Care MedicineJuntendo University Urayasu HospitalUrayasuJapan
| | - Go Ishimaru
- Department of General Internal MedicineSoka Municipal HospitalSokaJapan
| | - Haruki Imura
- Department of Infectious Diseases, Rakuwakai Otowa HospitalKyoto UniversityKyotoJapan,Department of Health Informatics, School of Public HealthKyoto UniversityKyotoJapan
| | - Hiromu Okano
- Department of Critical Care and Emergency MedicineNational Hospital Organization Yokohama Medical CenterYokohamaJapan
| | - Chihiro Narita
- Department of Emergency Medicine and Intensive Care MedicineShizuoka General HospitalShizuokaJapan
| | - Takuya Mayumi
- Department of Internal MedicineKanazawa Municipal HospitalKanazawaJapan
| | - Hideto Yasuda
- Department of Emergency and Critical Care MedicineJichi Medical University Saitama Medical CenterSaitamaJapan
| | - Kohei Yamada
- Department of Traumatology and Critical Care MedicineNational Defense Medical CollegeTokorozawaJapan
| | - Hiroyuki Yamada
- Department of Primary Care and Emergency MedicineKyoto University HospitalKyotoJapan
| | - Tatsuya Kawasaki
- Department of Pediatric Critical CareShizuoka Children's HospitalShizuokaJapan
| | - Nobuaki Shime
- Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health SciencesHiroshima UniversityHiroshimaJapan
| | - Kent Doi
- Department of Emergency and Critical Care Medicine, Graduate School of MedicineThe University of TokyoTokyoJapan
| | - Moritoki Egi
- Department of AnesthesiaKyoto University HospitalKyotoJapan
| | - Hiroshi Ogura
- Department of Traumatology and Acute Critical MedicineOsaka University Medical SchoolSuitaJapan
| | - Morio Aihara
- Department of Gastroenterology and HematologyHirosaki University Graduate School of MedicineHirosakiJapan
| | - Shigeki Kushimoto
- Division of Emergency and Critical Care MedicineTohoku University Graduate School of MedicineSendaiJapan
| | - Osamu Nishida
- Department of Anesthesiology and Critical Care MedicineFujita Health University School of MedicineToyoakeJapan
| | | |
Collapse
|
4
|
Yamakawa K. Special Issue on "Disseminated Intravascular Coagulation: Current Understanding and Future Perspectives". J Clin Med 2022; 11:jcm11123315. [PMID: 35743386 PMCID: PMC9225217 DOI: 10.3390/jcm11123315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 06/08/2022] [Indexed: 12/10/2022] Open
Affiliation(s)
- Kazuma Yamakawa
- Department of Emergency and Critical Care Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan
| |
Collapse
|
5
|
Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19. Sci Rep 2022; 12:9147. [PMID: 35650227 PMCID: PMC9159042 DOI: 10.1038/s41598-022-12834-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 05/17/2022] [Indexed: 12/14/2022] Open
Abstract
Recently, immune response to coronavirus disease (COVID-19) has attracted attention where an association between higher antibody titer and worsening disease severity has been reported. However, our experiences with severe COVID-19 patients with low antibody titers led to hypothesizing that suppressed humoral immune response may be associated with poorer prognosis in severe COVID19. In this study, antibody titers in severe COVID19 patients were measured at 7, 10, 12, and 14 days after onset. Patients were divided into survivors and non-survivors. SARS-CoV-2 IgM in survivors and non-survivors were 0.06 AU and 0.02 AU (P = 0.048) at 10 days, 0.1 AU and 0.03 AU (P = 0.02) at 12 days, and 0.17 AU and 0.06 AU (P = 0.02) at 14 days. IgG in survivors and non-survivors were 0.01 AU and 0.01 AU (P = 0.04) at 7 days, 0.42 AU and 0.01 AU (P = 0.04) at 12 days, and 0.42 AU and 0.01 AU (P = 0.02) at 14 days. Multivariate analysis showed better survival among patients with IgM positivity at 12 days (P = 0.04), IgG positivity at 12 days (P = 0.04), IgM positivity at 14 days (P = 0.008), and IgG positivity at 14 days (P = 0.005). In severe COVID-19, low antibody titers on days 12 and 14 after onset were associated with poorer prognosis.
Collapse
|
6
|
Th1 cytokine endotype discriminates and predicts severe complications in COVID-19. Eur Cytokine Netw 2022; 33:25-36. [PMID: 36266985 PMCID: PMC9595088 DOI: 10.1684/ecn.2022.0477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Treatment of severe and critical cases of coronavirus disease 2019 (COVID-19) is still a top priority in public health. Previously, we reported distinct Th1 cytokines related to the pathophysiology of severe COVID-19 condition. In the present study, we investigated the association of Th1 and Th2 cytokine/chemokine endotypes with cell-mediated immunity via multiplex immunophenotyping, single-cell RNA-Seq analysis of peripheral blood mononuclear cells, and analysis of the clinical features of COVID-19 patients. Based on serum cytokine and systemic inflammatory markers, COVID-19 cases were classified into four clusters of increasing (I-IV) severity. Two prominent clusters were of interest and could be used as prognostic reference for a targeted treatment of severe COVID-19 cases. Cluster III reflected severe/critical pathology and was characterized by decreased in CCL17 levels and increase in IL-6, C-reactive protein CXCL9, IL-18, and IL-10 levels. The second cluster (Cluster II) showed mild to moderate pathology and was characterized by predominated CXCL9 and IL-18 levels, levels of IL-6 and CRP were relatively low. Cluster II patients received anti-inflammatory treatment in early-stage, which may have led prevent disease prognosis which is accompanied to IL-6 and CRP induction. In Cluster III, a decrease in the proportion of effector T cells with signs of T cell exhaustion was observed. This study highlights the mechanisms of endotype clustering based on specific inflammatory markers in related the clinical outcome of COVID-19.
Collapse
|
7
|
Ahmeti S, Keske Ş, Namani-Avdiu S, Ajazaj-Berisha L, Vishaj A, Sadik I, Alimusaj M, Hoti F, Ahmeti H, Sait B, Çakar N, Ergönül Ö. Management of COVID-19 Cases in Kosova. INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY 2022; 4:144-147. [PMID: 38633341 PMCID: PMC10986587 DOI: 10.36519/idcm.2022.125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 05/19/2022] [Indexed: 04/19/2024]
Affiliation(s)
- Salih Ahmeti
- Department of Infectious Diseases, University of Prishtina "Hasan Prishtina", Kosova
| | - Şiran Keske
- Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, Istanbul, Turkey
- Koç University İşbank Center for Infectious Diseases, Istanbul, Turkey
| | - Sadije Namani-Avdiu
- Department of Infectious Diseases, University of Prishtina "Hasan Prishtina", Prishtina, Kosova
| | - Lindita Ajazaj-Berisha
- Department of Infectious Diseases, University of Prishtina "Hasan Prishtina", Prishtina, Kosova
| | - Arben Vishaj
- Department of Infectious Diseases, University of Prishtina "Hasan Prishtina", Prishtina, Kosova
| | - Izet Sadik
- Department of Infectious Diseases, University of Prishtina "Hasan Prishtina", Prishtina, Kosova
| | - Mentor Alimusaj
- Department of Anesthesiology, Clinical Center of Kosova, University of Prishtina, Prishtina, Kosova
| | - Faik Hoti
- Department of Public Health, Ministry of Health, Prishtina, Kosovo
| | - Hysen Ahmeti
- Family Medical Center of Prishtina, Prishtina, Kosova
| | - Bilgin Sait
- Department of Internal Medicine, American Hospital, İstanbul, Turkey
| | - Nahit Çakar
- Department of Anesthesiology and Intensive Care Unit, Koç University School of Medicine, İstanbul, Turkey
| | - Önder Ergönül
- Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, Istanbul, Turkey
- Koç University İşbank Center for Infectious Diseases, Istanbul, Turkey
| |
Collapse
|
8
|
Levy G, Guglielmelli P, Langmuir P, Constantinescu S. JAK inhibitors and COVID-19. J Immunother Cancer 2022; 10:jitc-2021-002838. [PMID: 35459733 PMCID: PMC9035837 DOI: 10.1136/jitc-2021-002838] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/28/2022] [Indexed: 12/11/2022] Open
Abstract
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to the—possibly altered—response to the SARS-CoV-2. They act via a family of more than 40 transmembrane receptors that are coupled to one or several of the 4 Janus kinases (JAKs) coded by the human genome, namely JAK1, JAK2, JAK3, and TYK2. Once activated, JAKs act on pathways for either survival, proliferation, differentiation, immune regulation or, in the case of type I interferons, antiviral and antiproliferative effects. Studies of graft-versus-host and systemic rheumatic diseases indicated that JAK inhibitors (JAKi) exert immunosuppressive effects that are non-redundant with those of corticotherapy. Therefore, they hold the potential to cut-off pathological reactions in COVID-19. Significant clinical experience already exists with several JAKi in COVID-19, such as baricitinib, ruxolitinib, tofacitinib, and nezulcitinib, which were suggested by a meta-analysis (Patoulias et al.) to exert a benefit in terms of risk reduction concerning major outcomes when added to standard of care in patients with COVID-19. Yet, only baricitinib is recommended in first line for severe COVID-19 treatment by the WHO, as it is the only JAKi that has proven efficient to reduce mortality in individual randomized clinical trials (RCT), especially the Adaptive COVID-19 Treatment Trial (ACTT-2) and COV-BARRIER phase 3 trials. As for secondary effects of JAKi treatment, the main caution with baricitinib consists in the induced immunosuppression as long-term side effects should not be an issue in patients treated for COVID-19. We discuss whether a class effect of JAKi may be emerging in COVID-19 treatment, although at the moment the convincing data are for baricitinib only. Given the key role of JAK1 in both type I IFN action and signaling by cytokines involved in pathogenic effects, establishing the precise timing of treatment will be very important in future trials, along with the control of viral replication by associating antiviral molecules.
Collapse
Affiliation(s)
- Gabriel Levy
- Signal Transduction and Molecular Hematology, Ludwig Institute for Cancer Research, Brussels, Belgium.,Signal Transduction on Molecular Hematology, de Duve Institute, Université Catholique de Louvain, Bruxelles, Belgium.,WELBIO, Walloon Excellence in Life Sciences and Biotechnology, Brussels, Belgium
| | - Paola Guglielmelli
- Department of Clinical and Experimental Medicine, University of Florence, Firenze, Italy.,Center of Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
| | - Peter Langmuir
- Oncology Targeted Therapeutics, Incyte Corp, Wilmington, Delaware, USA
| | - Stefan Constantinescu
- Signal Transduction and Molecular Hematology, Ludwig Institute for Cancer Research, Brussels, Belgium .,Signal Transduction on Molecular Hematology, de Duve Institute, Université Catholique de Louvain, Bruxelles, Belgium.,WELBIO, Walloon Excellence in Life Sciences and Biotechnology, Brussels, Belgium.,Nuffield Department of Medicine, Oxford University, Ludwig Institute for Cancer Research, Oxford, UK
| |
Collapse
|
9
|
Kawakami A, Yamakawa K, Nishioka D, Ota K, Kusaka Y, Umegaki O, Ito Y, Takasu A.
PaO
2
/
FiO
2
ratio responsiveness to prone positioning in intubated patients with severe
COVID
‐19: a retrospective observational study. Acute Med Surg 2022; 9:e765. [PMID: 35677680 PMCID: PMC9167425 DOI: 10.1002/ams2.765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Accepted: 05/15/2022] [Indexed: 12/15/2022] Open
Abstract
Aim Prone positioning of coronavirus disease 2019 (COVID‐19) patients could improve oxygenation. However, clinical data on prone positioning of intubated COVID‐19 patients are limited. We investigated trends of PaO2 / FiO2 ratio values in patients during prone positioning to identify a predictive factor for early detection of patients requiring advanced therapeutic intervention such as extracorporeal membrane oxygenation (ECMO). Methods This retrospective, observational cohort study was undertaken between April 2020 and May 2021 in a tertiary referral hospital for COVID‐19 in Osaka, Japan. We included intubated adult COVID‐19 patients treated with prone positioning within the first 72 h of admission to the intensive care unit and followed them until hospital discharge or death. Primary outcomes were in‐hospital mortality and escalation of care to ECMO. We used unsupervised k‐means clustering modeling to categorize COVID‐19 patients by PaO2 / FiO2 ratio responsiveness to prone positioning. Results The final study cohort comprised 54 of 155 consecutive severe COVID‐19 patients. Three clusters were generated according to trends in PaO2 / FiO2 ratios during prone positioning (cluster A, n = 16; cluster B, n = 24; cluster C, n = 14). Baseline characteristics of all clusters were almost similar. Cluster A (no increase in PaO2 / FiO2 ratio during prone positioning) had a significantly higher proportion of patients placed on ECMO or who died (6/16, 37.5%). Numbers of patients with ECMO and with in‐hospital death were significantly different between the three groups (p = 0.017). Conclusion In Japanese patients intubated due to COVID‐19, clinicians should consider earlier escalation of treatment, such as facility transfer or ECMO, if the PaO2 / FiO2 ratio does not increase during initial prone positioning.
Collapse
Affiliation(s)
- Akiko Kawakami
- Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan
| | - Kazuma Yamakawa
- Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan
| | - Daisuke Nishioka
- Department of Medical Statistics, Research and Development Center Osaka Medical and Pharmaceutical University Takatsuki Japan
| | - Koshi Ota
- Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan
| | - Yusuke Kusaka
- Department of Anesthesiology Osaka Medical and Pharmaceutical University Takatsuki Japan
| | - Osamu Umegaki
- Intensive Care Unit Osaka Medical and Pharmaceutical University Hospital Takatsuki Japan
| | - Yuri Ito
- Department of Medical Statistics, Research and Development Center Osaka Medical and Pharmaceutical University Takatsuki Japan
| | - Akira Takasu
- Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan
| |
Collapse
|
10
|
Okano H, Furuya R, Niida S, Minami S, Horiuchi H, Suzuki N, Otsuka T, Miyazaki H. Methylprednisolone pulse therapy for critically ill patients with coronavirus disease 2019: A
single‐center
retrospective observational study. Acute Med Surg 2022; 9:e782. [PMID: 36092466 PMCID: PMC9448714 DOI: 10.1002/ams2.782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 08/17/2022] [Indexed: 12/15/2022] Open
Affiliation(s)
- Hiromu Okano
- Department of Emergency and Critical Care Medicine National Hospital Organization Yokohama Medical Center Yokohama Japan
- International University of Health and Welfare Graduate School of Public Health Tokyo Japan
| | - Ryosuke Furuya
- Department of Emergency and Critical Care Medicine National Hospital Organization Yokohama Medical Center Yokohama Japan
- Department of Emergency Medicine, Graduate School of Medicine Yokohama City University Yokohama Japan
| | - Shoko Niida
- Department of Emergency and Critical Care Medicine National Hospital Organization Yokohama Medical Center Yokohama Japan
- Department of Emergency Medicine, Graduate School of Medicine Yokohama City University Yokohama Japan
| | - Sakura Minami
- Department of Emergency Medicine, Graduate School of Medicine Yokohama City University Yokohama Japan
| | - Hiroshi Horiuchi
- Department of Emergency and Critical Care Medicine National Hospital Organization Yokohama Medical Center Yokohama Japan
| | - Naoya Suzuki
- Department of Emergency and Critical Care Medicine National Hospital Organization Yokohama Medical Center Yokohama Japan
- Department of Emergency Medicine, Graduate School of Medicine Yokohama City University Yokohama Japan
| | - Tsuyoshi Otsuka
- Department of Emergency and Critical Care Medicine National Hospital Organization Yokohama Medical Center Yokohama Japan
- Department of Emergency Medicine, Graduate School of Medicine Yokohama City University Yokohama Japan
| | - Hiroshi Miyazaki
- Department of Emergency and Critical Care Medicine National Hospital Organization Yokohama Medical Center Yokohama Japan
| |
Collapse
|